Last $2.07 USD
Change Today +0.03 / 1.47%
Volume 353.3K
RIGL On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

rigel pharmaceuticals inc (RIGL) Snapshot

Open
$2.08
Previous Close
$2.04
Day High
$2.10
Day Low
$1.98
52 Week High
03/17/14 - $5.00
52 Week Low
10/22/14 - $1.56
Market Cap
181.7M
Average Volume 10 Days
483.5K
EPS TTM
$-0.97
Shares Outstanding
87.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RIGEL PHARMACEUTICALS INC (RIGL)

rigel pharmaceuticals inc (RIGL) Related Businessweek News

No Related Businessweek News Found

rigel pharmaceuticals inc (RIGL) Details

Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Its product development programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor that intends to enter Phase III clinical trials for immune thrombocytopenic purpura and a Phase II clinical trial for immunoglobulin A nephropathy; R348, a topical janus kinase/SYK inhibitor in Phase II clinical trials for the treatment of keratoconjunctivitis sicca or chronic dry eye; R118, an adenosine monophosphate-activated protein kinase activator that intends to enter Phase I clinical trial; and two oncology product candidates in Phase I development. It also has small molecule discovery programs in muscle wasting. Rigel Pharmaceuticals, Inc. has collaboration agreement Daiichi Sankyo to pursue research related to a specific target from a class of drug targets called ligases that control cancer cell proliferation through protein degradation; and a license agreement with BerGenBio AS for the development and commercialization of an oncology program. The company was founded in 1996 and is based in South San Francisco, California.

129 Employees
Last Reported Date: 03/4/14
Founded in 1996

rigel pharmaceuticals inc (RIGL) Top Compensated Officers

Chairman, Chief Executive Officer and Member ...
Total Annual Compensation: $695.1K
President and Chief Operating Officer
Total Annual Compensation: $551.7K
Co-Founder, Executive Vice President, Directo...
Total Annual Compensation: $559.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $441.3K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $521.3K
Compensation as of Fiscal Year 2013.

rigel pharmaceuticals inc (RIGL) Key Developments

Rigel Pharmaceuticals, Inc. Reports Unaudited Financial Results for the Third Quarter and Nine Months Ended September 30, 2014

Rigel Pharmaceuticals, Inc. reported unaudited financial results for the third quarter and nine months ended September 30, 2014. For the third quarter of 2014, the company reported a net loss of $20.9 million, or $0.24 per basic and diluted share, compared to a net loss of $23.8 million, or $0.27 per basic and diluted share, for the same period of 2013. Loss from operations was $21,040,000 compared to $23,930,000 a year ago. For the nine months ended September 30, 2014, the company reported a net loss of $68.6 million, or $0.78 per basic and diluted share, compared to a net loss of $72.2 million, or $0.83 per basic and diluted share, for the same period of 2013. Loss from operations was $68,881,000 compared to $72,525,000 a year ago.

Rigel Pharmaceuticals, Inc. Reiterates Clinical Focus on Fostamatinib for ITP and IgA Nephropathy

Rigel Pharmaceuticals, Inc. announced that R348, its ophthalmic JAK/SYK inhibitor, did not meet the primary or secondary endpoints in a recently completed Phase 2 clinical study in patients with dry eye disease. The endpoints were measured by changes in corneal fluorescein staining, conjunctival staining, tear production and dry eye symptom scores from baseline over 12 weeks of treatment versus placebo. No significant adverse events were reported in the trial. Rigel has decided not to initiate any new studies of R348 for this indication, but is continuing its Phase 2 study of dry eye in patients with graft versus host disease (GvHD). The company is focusing its resources on advanced clinical studies of fostamatinib in two indications. The fostamatinib programs include a recently initiated Phase 3 study in patients with immune thrombocytopenic purpura (ITP) and its planned Phase 2 study in patients with IgA Nephropathy (IgAN), an autoimmune disease of the kidneys, in fourth quarter of 2014. Demonstrating clinical benefit in patients with dry eye disease remains a significant challenge for the pharmaceutical industry, said James M. Gower, chairman and chief executive officer of Rigel. The company's energies and resources going forward are committed to supporting fostamatinib in its advanced clinical development. In addition, Rigel announced it has discontinued its indirect AMPK activator program, R118, due to its side-effect profile in Phase 1 clinical trials. However, the company will continue its direct AMPK activator research program.

Rigel Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Rigel Pharmaceuticals, Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported loss from operations of $25,456,000 against $22,885,000 a year ago. Net loss was $25,391,000 against $22,768,000 a year ago. Basic and diluted loss per share was $0.29 against $0.26 a year ago. For the six months, the company reported loss from operations of $47,841,000 against $48,595,000 a year ago. Net loss was $47,694,000 against $48,342,000 a year ago. Basic and diluted loss per share was $0.54 against $0.55 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RIGL:US $2.07 USD +0.03

RIGL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $1.26 USD -0.02
Array BioPharma Inc $3.76 USD +0.05
CTI BioPharma Corp $2.22 USD +0.05
Exelixis Inc $1.76 USD +0.02
Progenics Pharmaceuticals Inc $6.77 USD +0.35
View Industry Companies
 

Industry Analysis

RIGL

Industry Average

Valuation RIGL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 31.6x
Price/Book 1.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RIGEL PHARMACEUTICALS INC, please visit www.rigel.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.